Coming in as the 13th largest position in the ARKG ETF with a 2.68% weight (as of 02/18/2021), CRISPR Therapeutics AG is arguably one of Cathie Wood's favorite play in this space.
Since hitting the Highs of $220.20 on 01/15/2021,
CRSP has been on a steady decline to the lows of $142.15, forming a clear Head & Shoulder pattern on the daily chart in the process. Over the last 2 days,
CRSP has been attempting to break the neckline of the H&S, but with no success - as we see rejection off the neckline and volume picking up with an upward push in price.
Today, we see price trading upwards of $147.12, stabilizing at $150.
Next, I expect
CRSP to continue closing above the neckline, subsequently testing and breaking the next 2 resistance to complete the invalidation of the H&S.
My target is $181.42. Please set SL based on your own risk tolerance.
This is not investment advice so please do your own due diligence!
Support this idea with likes and share your thoughts below.
Since hitting the Highs of $220.20 on 01/15/2021,
Today, we see price trading upwards of $147.12, stabilizing at $150.
Next, I expect
My target is $181.42. Please set SL based on your own risk tolerance.
This is not investment advice so please do your own due diligence!
Support this idea with likes and share your thoughts below.
Trade closed: stop reached
The stop-loss that I set for myself for the H&S invalidation play was absolutely obliterated today. We have broken below both the neckline of the head & shoulder and the support of the bullish channel . This puts the level of $84 to $110 absolutely in play.Unless we are able to break back above the bullish channel and the neckline, the H&S pattern will complete itself. The daily RSI may be in the oversold territory now, but considering the nature of our correcting market,
As such, the downside risk for
This is not investment advice so please do your own due diligence!
Support this idea with likes and share your thoughts below.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.